CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Krupka, Christina; Kufer, Peter; Kischel, Roman; Zugmaier, Gerhard; Bögeholz, Jan; Köhnke, Thomas; S Lichtenegger, Felix; Schneider, Stephanie; H Metzeler, Klaus; Fiegl, Michael; Spiekermann, Karsten; A Baeuerle, Patrick; Hiddemann, Wolfgang; Riethmüller, Gert; Subklewe, Marion

doi:10.1182/blood-2013-08-523548

Public

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Published in Blood • Jan 16, 2014

Authors:

Christina Krupka

Peter Kufer

Roman Kischel

Abstract

Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging (BiTE) antibody (AMG 330) for its suitability as a therapeutic agent in acute myeloid leukemia (AML). We first assessed CD33 ...

View

Paywalled

View Full Text

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Generate AI Take for this paper

Discussions